Gilenya Moves Towards Clinical Testing in ALS

With results in hand showing that Novartis’s new multiple sclerosis drug Gilenya is effective in ALS mouse models (see: http://rascalsfoundation.org/dilemma-when-1-drug-treats-2-diseases/), ALS TDI turns its sights to human clinical trials. How does a non-profit biotech find the resources to run a costly Phase II clinical trial? Committed collaborators, including its pharma partner Novartis, who will be providing the drug at no cost.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail